Differential Expression of Psoriasin Messenger RNA between in Situ and Invasive Human Breast Carcinoma

Etienne Leygue, Linda Snell, Tamara Hiller, Helmut Dotzlau, Kate Hole, Leigh C. Murphy, and Peter H. Watson

Departments of Biochemistry and Molecular Biology [E. L. H. D., L. C. M.] and Pathology [L. S. T. H., K. H., P. H. W.]. University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, MB R3E 0W3 Canada

Abstract

The mRNA encoding the calcium-binding protein psoriasin was identified as being more highly expressed in the in situ versus the invasive component of the same breast tumor. Reverse transcription-PCR analysis of total RNA extracted from three independent cases of ductal carcinoma in situ of the comedo type and three cases of high-grade invasive ductal carcinoma revealed a detectable level of psoriasin mRNA expression in the in situ lesions only. Similar analysis performed on total RNA extracted from frozen sections of 32 independent breast samples, representing a continuum from normal to invasive tumor, confirmed high psoriasin expression in ductal carcinoma in situ of the comedo type only. The possible functional role of the psoriasin protein in breast tumor cells remains to be determined.

Introduction

The currently accepted model of breast tumorigenesis is based on epidemiological and histological observations. These have defined a series of morphological changes including epithelial hyperplasia, atypical hyperplasia, and in situ carcinoma that may parallel the process of evolution toward an invasive breast cancer (1). It is believed that the initial transformation event involves epithelial cells in the terminal ductal unit. Sequential additional genetic alterations accumulate which contribute to the development of phenotypic changes such as altered patterns of growth, unrestricted proliferation, and the cytological appearance of malignancy which serve as the basis for the recognition of preinvasive DCIS. Further alterations within the cells in these in situ lesions may then lead to the acquisition of the invasive phenotype and other manifestations of tumor progression. The onset of invasive tumor cells, which are able to generate future metastasis, is perhaps the most critical step in breast tumor progression. However, little is known about the molecular mechanisms underlying this transition. Knowledge of these mechanisms is a necessary prerequisite to allow a better understanding of this critical step in tumor progression and may provide targets for new and possibly curative therapies (2). To address this issue, we have undertaken a study to identify genes which are differentially expressed between the DCIS and the invasive breast cancer components within any biopsy sample.

Materials and Methods

Human Breast Tissues

Human breast specimens were obtained from the Manitoba Breast Tumor Bank (University of Manitoba, Winnipeg, Manitoba, Canada). All cases in the bank have been rapidly frozen at -70°C after surgical removal and subsequently processed to create formalin-fixed and paraffin-embedded tissue blocks that are matched and oriented relative to a corresponding frozen tissue block. This facilitates interpretation of frozen tissue composition by reference to adjacent high-quality histological sections to map in situ and invasive compartments and to distinguish specific preneoplastic histological lesions.

Microdissection Case. To select a suitable microdissection case with which to start the study, 388 primary invasive ductal carcinomas were reviewed. Of these, 32% contained an identifiable in situ component and 17% contained a significant (i.e., >20% of the tumor component within the block) DCIS component. From this subset, a microdissection case showing DCIS associated with a small invasive carcinoma was identified. In the corresponding frozen tissue block, DCIS (solid and comedo type) was geographically distinct from an invasive ductal carcinoma component (Nottingham (3) grade 7), but both were associated with similar stromal elements and a sparse inflammatory host response.

Group 1. To confirm the differential expression between in situ and invasive lesions of the gene identified in the microdissection case, six additional frozen tissue samples, corresponding to six different patients, were selected. This selection of three DCIS (IS1, IS2, and IS3) and three invasive ductal carcinomas (IV1, IV2, and IV3) was achieved primarily on the basis of similarity in DCIS subtype, invasive ductal morphology, and grade to the corresponding components of the original microdissection case.

Group 2. To study the expression of the identified genes at different steps of tumorigenesis and progression, a second panel of 32 breast tissue frozen samples, corresponding to 32 different patients, was selected. This panel comprised 5 cases with normal breast tissue, 5 cases with PDWA, 3 cases with ADH, 12 cases with DCIS, and 7 cases with invasive ductal carcinoma. Histological diagnosis and confirmation of lesions in frozen sections were made by reference to the adjacent paraffin section using established criteria (4, 5). Normal breast tissues were obtained from normal tissues adjacent to tumors in mastectomy specimens. The subtypes among the DCIS cases included seven noncomedo and five comedo or mixed comedo/noncomedo types. The invasive carcinomas included three cases with good prognosis indicators (well-differentiated Nottingham grades 4 and 5, ER and PR positive, and axillary node negative) and four cases with poor prognosis indicators (poorly differentiated Nottingham grade 9, ER and PR negative, and axillary node positive).

RNA Extraction

DCIS and matched invasive components were microdissected as described previously (6) from five adjacent 20-μm frozen sections of the microdissection case. Corresponding RNA was extracted using a small-scale RNA extraction protocol (Tri-reagent; Molecular Research Center, Inc., Cincinnati, OH) as described previously (6, 7). Total RNA was similarly extracted from 20-μm frozen sections or from whole-tissue blocks for breast samples in groups 2 and 1, respectively.

4606
Isolation and Identification of Psoriasin mRNA as Overexpressed in the in Situ Compartment Compared to the Matched Invasive One

A recently described subtractive hybridization technique (8) was used to isolate mRNA species overexpressed in the DCIS relative to the invasive breast cancer compartment of the microdissection case. Briefly, in situ and immediately adjacent invasive tumor cell populations were microdissected. The corresponding RNAs were extracted and mRNAs were isolated by hybridization to oligo(dT) coupled magnetic beads (Dynal, New York, NY). Single-stranded cDNAs covalently bound to the beads (sscDNA IS-beads and sscDNA IV-beads for in situ and invasive compartments, respectively) were synthesized according to the manufacturer’s instructions. Oligo(dA) residues were then added to the 3’ ends using terminal transferase (Promega, Madison, WI), and strands complementary to sscDNA IS-beads (sscDNA IS) were synthesized using MboI-dT primer (5’-AGGGCGATCTTcccccccccc-3’). The sscDNA IS population was then equalized (autohybridized) and subtracted three times against sscDNA P1-beads. During these three rounds of subtraction, sscDNA IS common to both in situ and invasive compartments were captured by hybridization to complementary sscDNA IV-beads and subsequently removed from the solution. sscDNA IS in situ specific, remaining in the solution, were then amplified using radioactive PCR and MboI-dT primer. Labeled PCR products were then separated on 6% polyacrylamide gels containing 7 M urea (PAGE) and visualized with autoradiography. Bands were isolated from the dried gel, subcloned, and sequenced as described previously (7).

In Situ Hybridization

Paraffin-embedded (5-μm) breast tumor sections were analyzed by in situ hybridization according to a previously described protocol (9). The plasmid Pso-246 that consisted of a PCR II plasmid (Invitrogen, San Diego, CA) containing a 246-bp insert of psoriasis cDNA between bases 41 and 289 (9) was used as a template to generate sense and antisense riboprobes. 35S-labeled UTP riboprobes were synthesized using Riboprobe Systems (Promega) according to the manufacturer’s instructions. Sections from a psoriatic skin lesion, previously shown (9) to express a high level of psoriasis mRNA, were used as positive controls.

RT-PCR Analysis

RNA (600 ng) was reverse transcribed in a final volume of 15 μl as described previously (7). One μl of the reaction mixture was taken for subsequent amplification using PCR. PCR was performed as described previously (7) using either primers corresponding to psoriasis (sense 5’-AAGAAAAGATGAGACAACAC-3’ and antisense 5’-CCAGCAAGGACAGAACT-3’) or to the ubiquitously expressed GAPDH gene (sense 5’-ACCACTCTCTCCACACTGT-3’ and antisense 5’-CTCTGTGCTCTTGCTGGG-3’). To amplify cDNA corresponding to psoriasis, 30 cycles (30 s at 94°C, 30 s at 52°C, and 30 s at 72°C) of PCR were used. For amplification of GAPDH cDNA, PCR consisted of 30 cycles (1 min at 94°C, 1 min at 52°C, and 1 min at 72°C). PCR products were separated on 2% agarose gels before staining with ethidium bromide. Identity of the 246-bp long fragment corresponding to psoriasis was confirmed by subcloning and sequencing as described previously (7).

Northern Blot Analysis

Twenty μg of total RNA from in situ tumor IS1 (group 1) were analyzed using Northern blotting as described previously (10). The probe used consisted of a PCR product corresponding to a 246-bp fragment of psoriasis cDNA labeled by nick translation (Amersham, Oakville, Ontario). Nitrocellulose membranes were exposed for 72 h to Kodak XAR film at −70°C.

Results

Differential Expression of Psoriasin mRNA between in Situ and Invasive Compartments of a Selected Human Breast Tumor. To identify genes differentially expressed between in situ and invasive tumor cell populations, a matched sample of DCIS associated with a small invasive carcinoma was selected. In situ and immediately adjacent invasive compartments were microdissected and corresponding total RNA was extracted. These RNAs provided the substrate for a recently described subtractive hybridization technique to identify differentially expressed genes (8). cDNA corresponding to the calcium-binding protein psoriasis (9) or S100A7 (11) was identified as more highly expressed in the in situ breast cancer compartment (data not shown). To confirm this differential expression, in situ hybridization was performed on sections from a matched paraffin-embedded block that was a mirror image of the original microdissected frozen tissue block (Fig. 1). A strong signal was observed in the in situ region of the tumor using the psoriasis antisense probe, although a very weak one was observed overall in the matched invasive breast cancer compartment (Fig. 1A). No signal was observed using a psoriasis sense probe (Fig. 1B). Assessment of the sections at a higher magnification revealed that the psoriasis expression was confined to epithelial tumor cells of the in situ lesion (Fig. 1C) and that occasional cells from the invasive compartment also expressed psoriasis mRNA (Fig. 1D). No signal was detected in normal ducts adjacent to the in situ lesion (Fig. 1E). A strong expression of the psoriasis mRNA was detected in the positive control that consisted of skin from a psoriatic patient (Fig. 1F) previously shown to contain a high level of psoriasis mRNA (9).

Differential Expression of Psoriasin mRNA between Independent in Situ and Invasive Human Breast Tumors. To determine whether the differential expression of psoriasis mRNA within the in situ compartment was limited to the specific histology of the initial sample or whether it was a more general phenomenon, we selected an initial panel (group 1) of three in situ (IS1, IS2, and IS3) and three invasive (IV1, IV2, and IV3) unmatched ductal carcinomas derived from six different patients and possessing similar histologies to the respective components of the initial sample. Total RNA was extracted from whole-tissue blocks, and psoriasis mRNA expression was investigated using RT-PCR (Fig. 2). The expected 246-bp PCR product, corresponding in size to psoriasis mRNA, was observed in each of the in situ samples. In contrast, this PCR fragment was not detected in any of the invasive tumors. The identity of the PCR product was checked by sequencing (data not shown). This differential expression was not due to differences in input cDNA, as demonstrated by the similar intensity of the 178-bp fragment corresponding to the ubiquitously expressed GAPDH gene. Northern blot analysis performed on total RNA from in situ tumor IS1 confirmed the presence of the 0.45 kb long psoriasis mRNA (data not shown).

Psoriasis mRNA Expression Is Modified during Tumor Progression. Psoriasis mRNA expression was then investigated within a panel of histologically defined breast tissue samples chosen to represent different steps of tumorigenesis (group 2). Total RNA was extracted from frozen tissue sections and analyzed with RT-PCR. Three independent experiments were performed and gave the same results. Fig. 3 shows typical results observed. Psoriasis expression was weak or undetectable in normal breast tissues adjacent to tumor and in samples of breast PDWA. A signal corresponding to psoriasis mRNA was observed in some sections that contained ADH and in some DCIS lesions of the noncomedo type. Most of the DCIS of the comedo type expressed a comparatively high level of psoriasis mRNA as measured by this technique. An apparently lower signal was detected in those samples of invasive ductal carcinoma. The differences observed were unlikely due to differences in input cDNAs (as shown by similar intensity of GAPDH signals in each lane) or to differences in tumor cell content (assessed in immediately adjacent histological sections).

Differential PSORIASIN EXPRESSION IN BREAST CANCER

4607
Fig. 1. Formalin-fixed and paraffin-embedded sections of the initial microdissection case were studied with in situ hybridization, as described in "Materials and Methods," using psoriasin antisense (A, C, D, and E) or sense (B) 35S-labeled probes. A and B, in situ (left side of photograph) and invasive (right side of photograph) breast cancer in the same tissue section. In situ compartment (C), invasive compartment (D), and normal breast duct alongside a focus of DCIS (E) are shown at higher magnifications. F, Section of psoriatic skin from another individual studied with in situ hybridization using a psoriasin antisense probe and used as positive control. A, B, and F, ×30; C and D, ×200; and E, ×80.

Discussion

Psoriasin is a small calcium-binding protein of 11 kDa, belonging to the S100 gene family, of which the exact function is unknown (9, 12). The expression of the psoriasin gene has been described previously in psoriatic skin and other skin diseases (9, 13). Psoriasin mRNA was identified here as being more highly expressed in the in situ compartment than in the adjacent invasive breast tumor cell population within the same human breast tumor specimen. This differential expression between in situ and invasive lesions was confirmed using independent breast cancer tissue samples. Interestingly, RT-PCR performed on RNA extracted from whole invasive breast tumor tissue blocks did not allow the detection of psoriasin mRNA (Fig. 2), although in situ hybridization revealed that a few invasive cells express this mRNA (Fig. 1D). This probably resulted from the high dilution of the target transcript within total RNA from whole tumor. The subsequent observation of a weak signal corresponding to psoriasin in some invasive tumor samples when total RNA from tissue sections was analyzed (Fig. 3) and where such a dilution phenomenon is decreased supported this hypothesis.

Very recently, Moog-Lutz et al. (14) detected psoriasin mRNA in human invasive breast cancer cells both in vivo and in vitro. In that study, psoriasin mRNA was observed using Northern blot analysis in 17% of the RNA samples from a small series of primary carcinomas. However, using in situ hybridization, they detected psoriasin expression only in a small fraction of the invasive cancer cells. This last result is similar to what we have also observed using the same technique in invasive carcinoma (Fig. 1D). The relationship with DCIS and the transition from in situ to invasive carcinoma was not examined by Moog-Lutz et al. (14). It is interesting to note that in the

Fig. 2. RT-PCR analysis of psoriasin mRNA in three DCIS and three invasive ductal carcinomas (group 1): total RNA was extracted from three DCIS (IS1-3) and three invasive ductal carcinomas (IV1-3). RT-PCR was then performed as described in "Materials and Methods" to amplify psoriasin and GAPDH cDNAs. PCR products were separated on 1% agarose gels before staining with ethidium bromide. Black arrowhead, product corresponding to psoriasin; gray arrowhead, product corresponding to GAPDH. +, molecular weight marker (4X174 RF DNA/HaeIII fragments; Life Technologies, Inc., Grand Island, NY); C, negative control, no cDNA added during the PCR reaction.
involved in breast tumorigenesis. For example, altered expression of the Msi1 gene in murine breast cell lines can influence metastasis (17), and CAPL gene expression may correlate with invasiveness of breast cell lines (18). In contrast, expression of CaN19 was found to be more highly expressed in normal breast cells compared to cancer cells (19).

The mechanisms underlying the changes in psoriasin mRNA expression during tumor progression as well as the possible functional role of the encoded protein in breast tumor cells remain to be determined.

Acknowledgments

We thank Ingo Schroeder for his assistance during the set-up of the in situ hybridization assay. The Manitoba Breast Tumor Bank is supported by funding from the National Cancer Institute of Canada and the Terry Fox Foundation.

References

Differential Expression of Psoriasin Messenger RNA between \textit{in Situ} and Invasive Human Breast Carcinoma

Etienne Leygue, Linda Snell, Tamara Hiller, et al.


\textbf{Updated version} Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/56/20/4606

\textbf{E-mail alerts} Sign up to receive free email-alerts related to this article or journal.

\textbf{Reprints and Subscriptions} To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

\textbf{Permissions} To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.